Watchmaker Genomics Licenses CRISPR Technology to Improve DNA Sequencing Efficiency
The company plans to use CRISPR-Cas9 as a binding tool to address bottlenecks in next-generation sequencing workflows.
Read MorePosted by CLP Edit Staff | Feb 17, 2026 | Library Preparation Systems Flow |
The company plans to use CRISPR-Cas9 as a binding tool to address bottlenecks in next-generation sequencing workflows.
Read MorePosted by CLP Edit Staff | Feb 11, 2026 | Dementias & Alzheimer’s, Diagnostic Technologies, Lab Management |
The Elecsys pTau-181 test helps primary care clinicians rule out Alzheimer’s disease in symptomatic patients aged 55 and older.
Read MorePosted by CLP Edit Staff | Feb 10, 2026 | Molecular Diagnostic Analyzers |
BillionToOne has launched Northstar PGx and Northstar Select CH, two liquid biopsy add-on tests for advanced solid tumor therapy selection, enabling pharmacogenomic insights and clonal hematopoiesis detection from a single blood draw.
Read MorePosted by CLP Edit Staff | Feb 9, 2026 | Flu & Respiratory Infections |
Visby Medical and Watchmaker Genomics have partnered to develop at-home PCR respiratory tests designed to overcome molecular inhibitors found in unprocessed clinical samples, according to a joint announcement.
Read MorePosted by CLP Edit Staff | Feb 9, 2026 | Cancer |
Johns Hopkins researchers have developed a liquid biopsy that detects early-stage lung and breast cancers by measuring DNA methylation variation, showing high accuracy in a study published in Clinical Cancer Research.
Read More